奥氮平治疗食管癌患者化疗相关性呕吐的效果及安全性

目的 探讨奥氮平治疗食管癌患者化疗相关性呕吐的效果及安全性.方法 选择82不能手术的食管癌患者,随机分为对照组和观察组,各41例.两组均应用TP方案化疗,对照组托烷司琼和地塞米松预防呕吐,观察组在对照组基础上加用奥氮平治疗.结果 对照组急性化疗所致呕吐发生率为51.2％,观察组为29.3％,差异有统计学意义(P＜0.05);对照组延迟性化疗所致呕吐发生率为31.7％,观察组为9.8％,差异有统计学意义(P＜0.05);对照组4例出现不良反应,观察组7例,差异无统计学意义(P＞0.05).结论 奥氮平可有效预防食管癌患者化疗相关性呕吐,安全有效.

Olanzapine in treatment of chemotherapy-related nausea and vomiting in patients with esophageal cancer

Objective To investigate the efficacy and safety of olanzapine in the treatment of chemotherapy-related nausea and vomiting in patients with esophageal cancer.Methods 82 inoperable esophageal cancer patients were selected and randomly divided into a control group and an observation group,41 cases for each group.Both groups were treated with TP chemotherapy.The control group was treated with tropisetron and dexamethasone in prevention of vomiting;in addition,the observation group were treated with olanzapine.Results The incidence of acute vomiting caused by chemotherapy was 51.2％ in the control group and 29.3％ in the observation group,with a statistical difference (P＜0.05).The incidence of delayed chemotherapyinduced vomiting was 31.7％ in the control group and 9.8％ in the observation group,with a statistical difference (P＞0.05).4 eases occurred adverse reactions in the control group and 7 in the observation group,with no statistical difference (P＜0.05).Conclusions Olanzapine in the prevention of chemotherapy-related nausea and vomiting in patients with esophageal cancer is effective and safe.